Davis Polk advised Credit Suisse Securities (USA) LLC and Citigroup Global Markets Inc. as joint book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 3,450,000 shares of common stock of PTC Therapeutics, Inc., which included 450,000 shares from the full exercise of the underwriters’ option to purchase additional shares. The common stock is listed on the NASDAQ Global Select Market under the symbol “PTCT."   

Based in Plainfield, New Jersey, PTC Therapeutics is a biopharmaceutical company focused on the discovery and development of orally administered small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases. Its lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Sophia Hudson and associates Yasin Keshvargar and Jon B. Shields. The tax team included partner Michael Mollerus and associate Sam R. Van Peperstraete. Associates Natalie A. Thomas and David He provided intellectual property advice. The environmental team included counsel Loyti Cheng and associate Kevin J. Klesh. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.